Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. März 2012 09:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom to Present at 24th Annual ROTH Capital Conference

ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
09. März 2012 11:00 ET | Quelle: Aastrom Biosciences, Inc.

Webcast Alert: Aastrom to Report Fourth Quarter and Year-End 2011 Operating Results on Monday, March 12, 2012

ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
09. März 2012 11:00 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Completes $40 Million Financing

ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
29. Februar 2012 16:30 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T

ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
22. November 2011 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at Piper Jaffray 23rd Annual Health Care Conference in New York City

ANN ARBOR, Mich., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
14. November 2011 11:15 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Reports Positive 12-Month Results from the RESTORE-CLI Phase 2 Clinical Trial for Ixmyelocel-T in Patients with Critical Limb Ischemia

ANN ARBOR, Mich., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
11. November 2011 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences to Hold Research and Development Day Review for Investors on November 17, 2011

ANN ARBOR, Mich., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
08. November 2011 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Third Quarter 2011 Financial Results

ANN ARBOR, Mich., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
03. November 2011 09:00 ET | Quelle: Aastrom Biosciences, Inc.

New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to Feature Aastrom Biosciences

ANN ARBOR, Mich., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
01. November 2011 16:05 ET | Quelle: Aastrom Biosciences, Inc.

Final 12-Month Results From the Aastrom RESTORE-CLI Phase 2b Clinical Trial to be Presented at the American Heart Association Scientific Sessions 2011 on Monday, November 14, 2011

ANN ARBOR, Mich., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...

Vorherige Seite

Nächste Seite